Vidofludimus calcium by Immunic for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Recursion and Exscientia merge to form drug discovery company

The merger is anticipated to bolster therapeutic discovery collaborations. Credit: Max Acronym/Shutterstock. Recursion has agreed to merge with Exscientia to create a global technology-enabled drug

August 9, 2024

Pα+ Psychedelic Bulletin #153: MindMed Scraps Microdosing Program; Eagerly Anticipated Ibogaine Study Publishes; Compass Collaborates with Greenbrook; Gilgamesh’s GM-1020 Readout; and more… – Psychedelic Alpha

This Issue is a relatively long one, as it’s something of a catch-up for the holiday period. We look at psychedelic drug development news from

January 12, 2024

Cannabis Use Tied to Increased Risk of Severe COVID

Cannabis use was significantly associated with a greater risk of severe outcomes following a COVID-19 infection, according to a retrospective study that spanned the first

June 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.